Literature DB >> 9851540

Hydralazine-induced vasodilation involves opening of high conductance Ca2+-activated K+ channels.

L Bang1, J E Nielsen-Kudsk, N Gruhn, S Trautner, S A Theilgaard, S P Olesen, S Boesgaard, J Aldershvile.   

Abstract

The purpose of this study was to investigate whether high conductance Ca2+-activated K+ channels (BK(Ca)) are mediating the vasodilator action of hydralazine. In isolated porcine coronary arteries, hydralazine (1-300 microM), like the K+ channel opener levcromakalim, preferentially relaxed contractions induced by K+ (20 mM) compared with K+ (80 mM). In addition, concentration-relaxation curves for hydralazine (pD2 = 5.38 +/- 0.06; Emax = 85.9 +/- 3.6%) were shifted 10-fold to the right by the BK(Ca) blockers tetraethylammonium (1 mM) and iberiotoxin (0.1 microM). In contrast, nimodipine (a Ca2+-entry blocker), relaxed contractions induced by K+ (20 mM) and K+ (80 mM) equally and nimodipine-induced relaxations were neither antagonized by tetraethylammonium nor by iberiotoxin. In isolated perfused rat hearts, hydralazine (1 microM) increased coronary flow by 28.8 +/- 2.7%. Iberiotoxin (0.1 microM) suppressed this response by 82% (P < 0.05). In conscious, chronically catheterized rats the hypotensive response to hydralazine (0.6 mg kg(-1) min(-1)) was significantly reduced by 41% during infusion of iberiotoxin (0.1 mg kg(-1)). It is concluded, that opening of BK(Ca) takes part in the mechanism whereby hydralazine produces vasodilation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851540     DOI: 10.1016/s0014-2999(98)00701-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Suppression of K(+)-induced hyperpolarization by phenylephrine in rat mesenteric artery: relevance to studies of endothelium-derived hyperpolarizing factor.

Authors:  G R Richards; A H Weston; M P Burnham; M Félétou; P M Vanhoutte; G Edwards
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 2.  Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?

Authors:  Michel Félétou
Journal:  Br J Pharmacol       Date:  2009-01-29       Impact factor: 8.739

Review 3.  Drug treatment of hypertensive crisis in children.

Authors:  Christopher A Thomas
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

Review 4.  Acrolein-mediated injury in nervous system trauma and diseases.

Authors:  Riyi Shi; Todd Rickett; Wenjing Sun
Journal:  Mol Nutr Food Res       Date:  2011-08-08       Impact factor: 5.914

Review 5.  Novel epigenetic-based therapies useful in cardiovascular medicine.

Authors:  Claudio Napoli; Vincenzo Grimaldi; Maria Rosaria De Pascale; Linda Sommese; Teresa Infante; Andrea Soricelli
Journal:  World J Cardiol       Date:  2016-02-26

6.  Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension.

Authors:  Paul J Marvar; Salim R Thabet; Tomasz J Guzik; Heinrich E Lob; Louise A McCann; Connie Weyand; Frank J Gordon; David G Harrison
Journal:  Circ Res       Date:  2010-06-17       Impact factor: 17.367

7.  Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery.

Authors:  D C Ellershaw; A M Gurney
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 8.  Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers.

Authors:  Halis Suleyman; Abdulmecit Albayrak; Mehmet Bilici; Elif Cadirci; Zekai Halici
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

9.  Hydralazine target: from blood vessels to the epigenome.

Authors:  Claudia Arce; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Myrna Candelaria; Alfonso Dueñnas-Gonzalez
Journal:  J Transl Med       Date:  2006-02-28       Impact factor: 5.531

10.  Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson's disease: implication of acrolein and TRPA1.

Authors:  Liangqin Shi; Yazhou Lin; Yucheng Jiao; Seth A Herr; Jonathan Tang; Edmond Rogers; Zhengli Chen; Riyi Shi
Journal:  Transl Neurodegener       Date:  2021-04-28       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.